AR060840A1 - Moduladores bencimidazolicos de vr1 - Google Patents
Moduladores bencimidazolicos de vr1Info
- Publication number
- AR060840A1 AR060840A1 ARP070101901A ARP070101901A AR060840A1 AR 060840 A1 AR060840 A1 AR 060840A1 AR P070101901 A ARP070101901 A AR P070101901A AR P070101901 A ARP070101901 A AR P070101901A AR 060840 A1 AR060840 A1 AR 060840A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- amino
- aminocarbonylamino
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- -1 aminosulfonylamino Chemical group 0.000 abstract 5
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000008649 adaptation response Effects 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000004664 haloalkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000004995 haloalkylthio group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La invencion se refiere a compuestos de bencimidazol moduladores del VR1 a composiciones farmacéuticas que contienen tales compuestos y a un proceso de preparacion del compuesto. Estos compuestos son utiles para el tratamiento de la ansiedad, trastornos de pánico, respuestas de no adaptacion al estrés y dolor cronico. Reivindicacion 1: Un compuesto de formula (1) y una forma del mismo donde: las líneas punteadas entre las posiciones 1, 2 y 3 de la Formula (1) indican las posiciones de un doble enlace tautomerico, donde cuando se forma un doble enlace entre las posiciones 1 y 2, entonces R3b está presente y donde, cuando se forma un doble enlace entre las posiciones 2 y 3, entonces R3a está presente; p es 1 o 2; q es 0 o 1; r es 0, 1, 2 o 3; L es alquilo C1-3, alquenilo C2-3, alquinilo C2-3 o ciclopropilo; A1 se selecciona del grupo que consiste en fenilo, bifenilo, naftilo, piridinilo, quinolinil e indol; cada R1 se selecciona del grupo que consiste en hidroxi, ciano, halogeno, formilo, carboxi, alquilo, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, alquilcarbonilo C1-6, alcoxicarbonilo C1-6, alquiltio C1-6, alquilsulfonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-4, cicloalquil C3-8-alcoxi C1-4, cicloalquilC3-8-oxígeno, amino, (alquil C1-6)1-2amino, (cicloalquil C3-8)1-2amino, (cicloalquil C3-8-alquil C1-4)1-2amino, aminocarbonilo, (alquil C1-6)1-2 aminocarbonilo, alquilcarbonilamino C1-6, alcoxicarbonilamino C1-6, aminocarbonilamino, (alquil C1-6)1-2 aminocarbonilamino, alquilsulfonilamino C1-6, alquilsulfinilamino C1-6, aminosulfonilo, (alquil C1-4)1-2 aminosulfonilo, aminosulfonilamino y (alquil C1-6)1-2 aminosulfonilamino, donde el alquilo está opcionalmente sustituido con alcoxi C1-8, amino, (alquil C1-4)1-2amino, alquilcarbonilamino C1-6, alcoxicarbonilamino C1-6, aminocarbonilamino, (alquil C1-6)1-2 aminocarbonilamino, alquilsulfonilamino C1-6, aminosulfonilamino, (alquil C1-6)1-2aminosulfonilamino, hidroxi y fenilo, donde el fenilo está opcionalmente sustituido con uno, dos o tres sustituyentes independientemente seleccionados del grupo que consiste en halogeno, ciano, nitro, alquilo C1-6, alcoxi C1-6, alquiltio C1-6 y alquilsulfonilo C1-6 y donde, cada caso de alquilo y alcoxi está opcionalmente perfluorado; R2 se selecciona del grupo que consiste en halogeno, alquilo C1-4, alcoxi C1-4, alquilsulfonilo C1-4, nitro, amino, (alquil C1-4)1-2 amino y ciano, donde, cada caso de alquilo y alcoxi está opcionalmente perfluorado; cada R3a y R3b se selecciona del grupo que consiste en hidrogeno y alquilo C1-4 opcionalmente perfluorado; y cada R4 se selecciona del grupo que consiste en halogeno, nitro, ciano, carboxi, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, haloalcoxi C1-6, alcoxi C1-6 -alquilo C1-6, alquilcarbonilo C1-6, alquiltio C1-6, haloalquiltio C1-6, alquilsulfonilo C1-6, haloalquilsulfonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-4, cicloalquil C3-8-alcoxi C1-4, cicloalquil C3-8-oxígeno, amino, (alquil C1-6)1-2amino, (cicloalquil C3-8)1-2amino, (cicloalquil-C3-8-alquil C3-8)1-2 amino, aminocarbonilo, (alquil C1-6)1-2 aminocarbonilo, alquilcarbonilamino C1-6, alcoxicarbonilamino C1-6, aminocarbonilamino, (alquil C1-6)1-2 aminocarbonilamino, alquilsulfonilamino C1-6, haloalquilsulfonilamino C1-6, alquilsulfinilamino C1-6, aminosulfonilo y (alquil C1-4)1-2 aminosulfonilo, donde cada caso de alquilo está opcionalmente sustituido con uno, dos o tres sustituyentes independientemente seleccionados del grupo que consiste en alcoxi C1-8, amino, (alquil C1-4)1-2 amino, alquilcarbonilamino C1-6, alcoxicarbonilamino C1-6, aminocarbonilamino, (alquil C1-6)1-2 aminocarbonilamino, alquilsulfonilamino C1- 6, oxo e hidroxi y donde, cada caso de alquilo y alcoxi está opcionalmente perfluorado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79750406P | 2006-05-03 | 2006-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060840A1 true AR060840A1 (es) | 2008-07-16 |
Family
ID=38566108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101901A AR060840A1 (es) | 2006-05-03 | 2007-05-02 | Moduladores bencimidazolicos de vr1 |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US7951829B2 (es) |
| EP (1) | EP2021330B1 (es) |
| JP (1) | JP5302884B2 (es) |
| KR (1) | KR101434883B1 (es) |
| CN (1) | CN101511797B (es) |
| AR (1) | AR060840A1 (es) |
| AT (1) | ATE482201T1 (es) |
| AU (1) | AU2007248341C1 (es) |
| BR (1) | BRPI0709803B8 (es) |
| CA (1) | CA2651128C (es) |
| CO (1) | CO6160329A2 (es) |
| CR (1) | CR10479A (es) |
| CY (1) | CY1111269T1 (es) |
| DE (1) | DE602007009378D1 (es) |
| DK (1) | DK2021330T3 (es) |
| EA (1) | EA019386B1 (es) |
| EC (1) | ECSP088854A (es) |
| ES (1) | ES2350959T3 (es) |
| HR (1) | HRP20100700T1 (es) |
| IL (1) | IL194916A (es) |
| JO (1) | JO3602B1 (es) |
| MX (1) | MX2008014108A (es) |
| MY (1) | MY154595A (es) |
| NI (1) | NI200800290A (es) |
| NO (1) | NO341965B1 (es) |
| NZ (1) | NZ572251A (es) |
| PE (1) | PE20080065A1 (es) |
| PL (1) | PL2021330T3 (es) |
| PT (1) | PT2021330E (es) |
| RS (1) | RS51473B (es) |
| SI (1) | SI2021330T1 (es) |
| TW (1) | TWI419882B (es) |
| UA (1) | UA94749C2 (es) |
| UY (1) | UY30322A1 (es) |
| WO (1) | WO2007130780A2 (es) |
| ZA (1) | ZA200810234B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2551709T3 (es) * | 2006-12-15 | 2015-11-23 | Janssen Pharmaceutica, N.V. | Inhibidores Bencimidazola TRPV1 |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| US20090156598A1 (en) * | 2007-12-17 | 2009-06-18 | Lebsack Alec D | Imidazolopyrimidine modulators of TRPV1 |
| TW200942549A (en) * | 2007-12-17 | 2009-10-16 | Janssen Pharmaceutica Nv | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
| KR101252334B1 (ko) * | 2008-04-18 | 2013-04-08 | 주식회사 대웅제약 | 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
| US8232409B2 (en) | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
| US8217060B2 (en) | 2009-05-15 | 2012-07-10 | Janssen Pharmaceutica, Nv | Benzimidazole derivatives useful as TRP M8 receptor modulators |
| US8323805B2 (en) * | 2009-06-04 | 2012-12-04 | Nitto Denko Corporation | Emissive aryl-heteroaryl acetylenes |
| CN102002010A (zh) * | 2009-08-31 | 2011-04-06 | 住友化学株式会社 | 双噁唑啉基烷烃化合物的精制方法 |
| MX2013013330A (es) * | 2011-05-16 | 2014-07-09 | Cellceutix Corp | Compuestos para utilizar en el tratamiento de mucositis. |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| CN105229003B (zh) | 2013-03-14 | 2017-03-15 | 诺华股份有限公司 | 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物 |
| CA2917964A1 (en) * | 2013-07-11 | 2015-01-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| US9676728B2 (en) | 2013-10-30 | 2017-06-13 | Novartis Ag | 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof |
| JP6705458B2 (ja) * | 2015-09-08 | 2020-06-03 | 住友化学株式会社 | トリアゾール化合物の製造方法 |
| US10870630B2 (en) | 2016-11-01 | 2020-12-22 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
| AU2019262169B2 (en) * | 2018-05-03 | 2024-05-02 | Jiangsu Hengrui Medicine Co., Ltd. | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORy) and pharmaceutical uses thereof |
| CN108997398B (zh) * | 2018-07-23 | 2020-12-15 | 被忽略疾病药物研发组织 | 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法 |
| CN112745268B (zh) * | 2019-10-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | 苯并咪唑衍生物的晶型及制备方法 |
| US20220411380A1 (en) * | 2019-10-31 | 2022-12-29 | Jiangsu Hengrui Medicine Co., Ltd. | ACID ADDITION SALT OF RORy REGULATOR |
| WO2021248008A1 (en) | 2020-06-05 | 2021-12-09 | Innovation Pharmaceuticals Inc. | Arylamide compounds for treatment and prevention of viral infections |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| US6299796B1 (en) | 1997-12-18 | 2001-10-09 | Fuji Photo Film Co., Ltd. | Styryl compound, method for the preparation thereof and electroluminescent element employing the same |
| US6748803B1 (en) * | 2000-02-22 | 2004-06-15 | Simmonds Precison Products, Inc. | Liquid measurement system and shared interface apparatus for use therein |
| WO2004035549A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| SI1660492T1 (sl) * | 2003-07-28 | 2009-02-28 | Janssen Pharmaceutica Nv | Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H |
| WO2005042497A2 (en) * | 2003-10-28 | 2005-05-12 | Vertex Pharmaceuticals, Incorporated | Benzimidazoles useful as modulators of ion channels |
| WO2006058338A2 (en) * | 2004-11-29 | 2006-06-01 | Janssen Pharmaceutica N.V. | 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor |
| BRPI0714199A2 (pt) * | 2006-07-04 | 2012-12-25 | Janssen Pharmaceutica Nv | agonistas de canabinàide de benzimidazol que transportam um grupo heterocÍclico substituÍdo |
| ES2551709T3 (es) * | 2006-12-15 | 2015-11-23 | Janssen Pharmaceutica, N.V. | Inhibidores Bencimidazola TRPV1 |
-
2007
- 2007-04-13 US US11/734,984 patent/US7951829B2/en active Active
- 2007-04-17 ES ES07760746T patent/ES2350959T3/es active Active
- 2007-04-17 KR KR1020087029196A patent/KR101434883B1/ko active Active
- 2007-04-17 EP EP07760746A patent/EP2021330B1/en active Active
- 2007-04-17 HR HR20100700T patent/HRP20100700T1/hr unknown
- 2007-04-17 BR BRPI0709803A patent/BRPI0709803B8/pt active IP Right Grant
- 2007-04-17 MX MX2008014108A patent/MX2008014108A/es active IP Right Grant
- 2007-04-17 CA CA2651128A patent/CA2651128C/en active Active
- 2007-04-17 AT AT07760746T patent/ATE482201T1/de active
- 2007-04-17 CN CN2007800247619A patent/CN101511797B/zh active Active
- 2007-04-17 AU AU2007248341A patent/AU2007248341C1/en active Active
- 2007-04-17 PT PT07760746T patent/PT2021330E/pt unknown
- 2007-04-17 DE DE602007009378T patent/DE602007009378D1/de active Active
- 2007-04-17 UA UAA200813889A patent/UA94749C2/ru unknown
- 2007-04-17 PL PL07760746T patent/PL2021330T3/pl unknown
- 2007-04-17 RS RSP-2010/0493A patent/RS51473B/sr unknown
- 2007-04-17 NZ NZ572251A patent/NZ572251A/xx unknown
- 2007-04-17 EA EA200870497A patent/EA019386B1/ru unknown
- 2007-04-17 DK DK07760746.3T patent/DK2021330T3/da active
- 2007-04-17 JP JP2009509920A patent/JP5302884B2/ja active Active
- 2007-04-17 WO PCT/US2007/066748 patent/WO2007130780A2/en not_active Ceased
- 2007-04-17 SI SI200730410T patent/SI2021330T1/sl unknown
- 2007-04-25 JO JOP/2007/0165A patent/JO3602B1/ar active
- 2007-05-02 PE PE2007000543A patent/PE20080065A1/es active IP Right Grant
- 2007-05-02 TW TW096115519A patent/TWI419882B/zh active
- 2007-05-02 AR ARP070101901A patent/AR060840A1/es active IP Right Grant
- 2007-05-03 UY UY30322A patent/UY30322A1/es not_active Application Discontinuation
-
2008
- 2008-10-26 IL IL194916A patent/IL194916A/en active IP Right Grant
- 2008-10-29 CO CO08115664A patent/CO6160329A2/es unknown
- 2008-10-30 MY MYPI20084339A patent/MY154595A/en unknown
- 2008-10-31 EC EC2008008854A patent/ECSP088854A/es unknown
- 2008-11-03 NI NI200800290A patent/NI200800290A/es unknown
- 2008-12-02 NO NO20085031A patent/NO341965B1/no unknown
- 2008-12-02 ZA ZA2008/10234A patent/ZA200810234B/en unknown
- 2008-12-03 CR CR10479A patent/CR10479A/es not_active Application Discontinuation
-
2010
- 2010-12-17 CY CY20101101167T patent/CY1111269T1/el unknown
-
2011
- 2011-04-12 US US13/084,705 patent/US20110190344A1/en not_active Abandoned
- 2011-04-12 US US13/084,718 patent/US20110190364A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060840A1 (es) | Moduladores bencimidazolicos de vr1 | |
| AR095079A1 (es) | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| AR084425A1 (es) | Derivados heterociclicos de 8-azabiciclo[3.2.1]octan-8-ilo, composiciones farmaceuticas que los contienen, proceso para prepararlos e intermediarios y uso de los mismos para tratar patologias hepaticas tales como dislipemias e hipercolesterolemia entre otras | |
| AR076547A1 (es) | Compuestos bis-amida como insecticidas | |
| AR073348A1 (es) | Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
| AR064356A1 (es) | Inhibidores benzoimidazolicos de trpv1 | |
| AR071236A1 (es) | Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 | |
| AR076682A1 (es) | Compuestos herbicidas derivados de 6,6-dioxo-6-tia-1,4-diaza-naftaleno, intermediarios de sintesis de dichos compuestos, composiciones herbicidas que los contienen y metodo para utilizar dichos compuestos para controlar el crecimiento de plantas. | |
| ES2569539T3 (es) | Derivados de piperidin-4-il azetidina como inhibidores de JAK1 | |
| CR10138A (es) | 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina | |
| ECSP099755A (es) | Derivados de pirrolopiridina y su uso como inhibidores de bace | |
| AR059035A1 (es) | Insecticidas derivados de antranilamida | |
| PA8546301A1 (es) | Resolucion de sal quiral | |
| AR099823A1 (es) | Compuestos bicíclicos de 7 eslabones | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR083936A1 (es) | Derivados pirazolicos de bisamida aromaticas, composiciones insecticidas que los contienen y metodos de utilizacion de los mismos para combatir y controlar plagas | |
| CL2009000404A1 (es) | Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras. | |
| PA8666701A1 (es) | Nueva sal y polimorfos del inhibidor de la dpp-iv | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| UY30627A1 (es) | Inhibidores de metaloproteasas derivados de heterociclos | |
| BR112015025729A2 (pt) | métodos para dividir e para produzir um composto, composto, composição farmacêutica, agente profilático ou terapêutico, e, uso de um cristal | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| AR070740A1 (es) | Plaguicidas, un proceso de preparacion del compuesto, una composicion en base al compuesto y un procedimiento de aplicacion del mismo | |
| AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |